Certara (CERT)

The company’s platform combines quantitative tools with scientific consulting. Certara supports pharmaceutical, biotechnology, and academic customers in areas such as pharmacokinetics, pharmacodynamics, dose optimisation, clinical trial design, and evidence generation. By simulating how medicines may behave in different patient populations, its tools can help sponsors refine study designs, reduce unnecessary experimentation, and strengthen regulatory packages.

Certara operates globally, with a presence across the Americas, Europe, the Middle East and Africa, and Asia Pacific. The Americas represent its largest revenue-generating region, reflecting the concentration of pharmaceutical research, biotechnology funding, and regulatory activity in the United States. Its customers range from emerging biotech companies to large global drugmakers.

What distinguishes Certara is its position in the specialised field of model-informed drug development. Regulators and drug developers increasingly use computational methods to support dosing decisions, paediatric extrapolation, rare disease studies, and other complex development challenges. Certara benefits from this shift, but its performance depends on research and development spending by life sciences companies, demand for regulatory consulting, software adoption, and the pace of innovation in drug development. For investors, CERT offers exposure to the digital and analytical infrastructure behind modern medicine development rather than to a single therapeutic product.